UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.
Zacks
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.
Zacks
More News
Novo's Wegovy Pill Shows Weight Loss After Switching From Injections
NVO's Wegovy pill delivers an average weight loss of 4.1% after three months for adults switching from injectable GLP-1 therapies.
Zacks
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study
MRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.
Zacks
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
Novo's real-world study finds that patients who increase their Ozempic to 2 mg have a lower observed MACE risk than those who switch to Mounjaro.
Zacks
uniQure Plunges on Additional Data From Huntington's Disease Study
QURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month data add uncertainty.
Zacks
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
Iovance hits a 52-week high after raising its 2026 revenue outlook to $410-$420 million on strong demand for its marketed therapies.
Zacks
Here's Why You Should Add URGN Stock to Your Portfolio Now
UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.
Zacks
Best Momentum Stock to Buy for September 30th
SCL and ACIU made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 30, 2026.
Zacks
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo
ABBV wins FDA approval for Juvmo, expanding its Parkinson's portfolio with a once-daily oral treatment and potential $5B-plus PD opportunity.
Zacks
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.